Simulation analysis demonstrates modular treatment effect estimation in latent trial subgroups, suggesting increased statistical power from baseline predictors.
Latent subgroups arise when patients are randomized to an intended treatment, that can only be given for certain, treatable, patients. For biological efficacy, the relevant estimand is then the treatment effect in the subgroup of treatable patients, with the obvious issue that this subgroup is latent, identified only in the intervention arm. We present a modular framework for effect estimation in such latent subgroups. The framework consists of a core and three plug-in models, for subgroup membership and outcomes among treatable and non-treatable patients. The core computes maximum likelihood estimates using the EM algorithm, together with standard errors. It does so without any knowledge about the details of the plug-in models, giving the user great flexibility. The methods are implemented in an R package. The framework is validated in a simulation, where we also explore the use of predictors. Particularly intriguing are predictors of treatability, partly identifying the latent subgroup from baseline data. The results suggest that this can dramatically increase the power, while being robust against model misspecifications. Finally, the methods are applied to a prostate cancer trial.
No takes yet. Share an insight, caveat, or question.
Lindhagen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: